Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/56743
Title: Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC).
Authors: 
Mesh: 
Issue Date: 3-Mar-2020
Citation: Bone Marrow Transplant.2020;(55)9:1744-1753
Abstract: This study (NCT01288573) investigated plerixafor's safety and efficacy in children with cancer. Stage 1 investigated the dosage, pharmacokinetics (PK), pharmacodynamics (PD), and safety of plerixafor + standard mobilization (G-CSF ± chemotherapy). The stage 2 primary endpoint was successful mobilization (doubling of peripheral blood CD34+ cell count in the 24 h prior to first apheresis) in patients treated with plerixafor + standard mobilization vs. standard mobilization alone. In stage 1, three patients per age group (2-
PMID: 32127657
URI: https://hdl.handle.net/20.500.12530/56743
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > FIB H. Infantil U. Niño Jesús > Artículos

Files in This Item:
File SizeFormat 
PMC7452813.pdf579.15 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons